Marinus Pharmaceuticals, Inc. (MRNS)

Market Cap	77.32M
Revenue (ttm)	30.99M
Net Income (ttm)	-141.41M
Shares Out	54.64M
EPS (ttm)	-2.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	463,174
Open	1.440
Previous Close	1.440
Day's Range	1.400 - 1.460
52-Week Range	1.110 - 11.260
Beta	0.89
Analysts	Buy
Price Target	13.75 (+871.73%)
Earnings Date	May 9, 2024

About MRNS

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABA...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 31, 2014
• Employees: 165
• Stock Exchange: NASDAQ
• Ticker Symbol: MRNS

Financial Performance

In 2023, MRNS's revenue was $30.99 million, an increase of 21.63% compared to the previous year's $25.48 million. Losses were -$141.41 million, 613.6% more than in 2022.

Analyst Forecast

According to 8 analysts, the average rating for MRNS stock is "Buy." The 12-month stock price forecast is $13.75, which is an increase of 871.73% from the latest price.

Price Target

$13.75

(871.73% upside)

Analyst Consensus: Buy